Dave is trading 4.19% up at $334.97, with no clear company-specific or market-wide catalyst established. - UBS reiterated its Buy rating and $470 price target on October 1 following investor meetings; the report does not say this prompted the increase. - Major indices showed modest gains, with no broad move exceeding 0.5% that clearly explains Dave’s rise.